Article

Phase 2 pilot trial to optimise pharmacometric evaluations in Chagas disease (CHARM: CHAgas disease PharMacometrics)

2024-06-27

Abstract excerpt

Chagas disease is a neglected disease caused by Trypanosoma cruzi that currently affects about 7 million people in the Americas and the American diaspora. Only two drugs are available to treat Chagas disease, both are associated with a high incidence of adverse events, particularly in adults, and they are also complex to administer. New treatments are needed urgently, but there is no established method of evaluat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 38563247-dc8f-5256-aab5-9b8f92e87169
DOI: 10.12688/wellcomeopenres.21246.1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phase 2 pilot trial to optimise pharmacometric evaluations in Chagas disease (CHARM: CHAgas disease PharMacometrics)DOI 10.12688/wellcomeopenres.21246.1Read

Drug screening and development cascade for Chagas disease: an update of in vitro and in vivo experimental models.Semantic proximity Read

Evaluation of a Bayesian hierarchical pharmacokinetic-pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugsSemantic proximity Read

Trypanosoma cruzi DTU diversity, benznidazole response, and clinical manifestations of Chagas disease: a seventeen-year systematic review and meta-analysis.Semantic proximity Read

The Role of the Pharmacist in Health CareSemantic proximity Read

A Quantitative Systems Pharmacology Model of the Pathophysiology and Treatment of COVID-19 Predicts Optimal Timing of Pharmacological InterventionsSemantic proximity Read

Optimizing Amodiaquine Dosing in Nigeria: A Population Pharmacokinetic Study to Inform Seasonal Malaria ChemopreventionSemantic proximity Read

Design and selection of drug properties to increase the public health impact of next-generation seasonal malaria chemoprevention: a modelling studySemantic proximity Read

Network-Based Approaches Reveal Potential Therapeutic Targets for Host-Directed Antileishmanial Therapy Driving Drug RepurposingSemantic proximity Read

Trypanosoma cruzi Arequipa: a tool for Chagas disease drug discoverySemantic proximity Read

Critique of "First quantitative assessment of the effects of parasite control in dogs and cats in the UK": Re-examining Parasiticide-Industry-Funded Estimates of Parasite-Control Benefits in UK Dogs and CatsSemantic proximity Read

Characterizing the pharmacological interaction of the antimalarial combination artefenomel-piperaquine in healthy volunteers with induced blood stage<i>Plasmodium falciparum</i>Semantic proximity Read

Translation of a Human‐Based Malaria‐on‐a‐Chip Phenotypic Disease Model for In Vivo ApplicationsSemantic proximity Read